58452-00-9

Usage

Uses

3-Benzyloxy-4-methoxybenzoic acid is used as Pharmaceutical intermediates.

InChI:InChI=1/C15H14O4/c1-18-13-8-7-12(15(16)17)9-14(13)19-10-11-5-3-2-4-6-11/h2-9H,10H2,1H3,(H,16,17)

Upstream product

• 57535-57-6 methyl 3-(benzyloxy)-4-methoxy-benzoate 
• 93-07-2 Veratric acid 
• 121-34-6 3-methoxy-4-hydroxybenzoic acid 
• 100-44-7 benzyl chloride 
• 148235-40-9 3-benzyloxy-4-methoxybenzoic acid benzyl ester 
• 645-08-9 Isovanillic acid 
• 100-39-0 benzyl bromide 
• 6702-50-7 3-hydroxy-4-methoxybenzoate 
• 621-59-0 isovanillin 
• 6346-05-0 3-benzyloxy-4-methoxybenzaldehyde 

Downstream Products

• 87265-44-9 3-(benzyloxy)-N-(2-hydroxyethyl)-4-methoxybenzamide 
• 15778-86-6 (+/-)-corgoine 
• 65341-86-8 N-(4'-methoxybenzoyl)-7-benzyloxy-6-methoxytetrahydroisoquinoline-1 
• 5056-80-4 (+/-)-sendaverine 
• 87265-46-1 N-(3-benzyloxy-4-methoxybenzoyl)-N-(4'-methoxybenzyl)-2-aminoethanol 
• 87265-42-7 N-(4'benzyloxybenzoyl)-7-benzyloxy-6-methoxytetrahydroisoquinoline-1 
• 87265-45-0 N-(3-benzyloxy-4-methoxybenzoyl)-N-(4'-benzyloxybenzyl)-2-aminoethanol 
• 57535-57-6 methyl 3-(benzyloxy)-4-methoxy-benzoate 
• 1362627-03-9 C₂₅H₃₆N₂O₄ 
• 1362624-37-0 (S)-1-(3-benzyloxy-4-methoxyphenyl)-3-(1-phenyl-ethyl)-urea 
• 1362624-32-5 (S)-1-(3-hydroxy-4-methoxyphenyl)-3-(1-phenyl-ethyl)-urea 
• 1362624-42-7 C₁₈H₂₂N₂O₃ 
• 1362624-47-2 C₁₉H₂₂N₂O₃ 
• 1362624-50-7 C₂₀H₂₄N₂O₅ 

Relevant academic research and scientific papers

COMPLEMENT MODULATORS AND RELATED METHODS

The present disclosure presents compounds and compositions that interact with complement components. Some compounds inhibit complement activity. Included are small molecule compounds and compositions that function as C5 inhibitor compounds. Methods for inhibiting complement activity and methods of treating complement-related indications with the C5 inhibitor compounds and compositions are provided.

Synthesis of rocaglamide derivatives and evaluation of their Wnt signal inhibitory activities

Rocaglamides are bioactive natural compounds which have a cyclopenta[b]benzofuran core structure. The total synthesis of a reported natural product, 3′-hydroxymethylrocaglate (5), was achieved using [3 + 2] cycloaddition between 3-hydroxyflavone and methyl cinnamate. We also describe the synthesis of rocaglamide heterocycle derivatives and evaluate their Wnt signal inhibitory activities. Compounds 4, 5, 22a, 22b, 22c and 23c showed potent Wnt signal inhibitory activity.

A urea compound, preparation method and its use

Provided are a urea compound having a structure as represented by general formula I, preparation method thereof, pharmaceutical composition containing the compound, and uses thereof in the preparation of drugs for treating inflammatory response, immune hyperactivity and organ transplantation rejection, wherein R1-R7, X, Y and n in the general formula are as defined in the specification and the claims.

With anti-tumor activity of the benzamide compound and its preparation method and application

The invention discloses a benzamide compound with antitumor activity as well as a preparation method and application thereof. The structural formula of the compound is shown in the specification, wherein in the structural formula, R1 is hydrogen or halogen; R2 is alkoxy with carbon number of 1-4; the terminal of R2 is replaced by tert-amido; R2 is linked to the para-position of benzamide via oxygen atoms; R3 is one of hydroxyl or methoxyl; R4 is the other one of hydroxyl or methoxyl. The compound has good tumor cell inhibiting activity in vitro and can be used for preparing antitumor drugs, especially anti-hepatoma drugs and anti-breast cancer drugs. The preparation method of the benzamide compound, provided by the invention, has the advantages that the raw materials are accessible, the reaction conditions are mild, the reaction process is simple to operate, and the used reagent is cheap.

NOVEL GLYCOSYLTRANSFERASE, NOVEL GLYCOSYLTRANSFERASE GENE, AND NOVEL GLYCOSYL DONOR COMPOUND

An object of the present invention is to provide a sugar donating reagent comprising a sugar donor compound other than a sugar nucleotide and an enzyme capable of catalyzing a glycosyl transfer reaction using a sugar donor compound other than a sugar nucleotide. The present invention provides the following: a sugar donating reagent containing a compound of formula (A): wherein R 1 is independently selected from hydrogen, or C 1-6 alkyl, C 2-6 alkenyl, and C 2-6 alkynyl in which each of the groups is unsubstituted or substituted with one or more groups selected from OH, F, Cl, Br, I, CN, NO 2 , and SO 2 , n is 0, 1, 2, 3, 4 or 5, m is 0 or 1, and X represents a monosaccharide bound via a 2 bond on its anomeric carbon; a glycosyltransferase capable of catalyzing a glycosyl transfer reaction using the sugar donor; and a glycosyltransferase gene comprising DNA encoding the glycosyltransferase.

HETEROAROMATIC DERIVATIVES AND PHARMACEUTICAL APPLICATIONS THEREOF

Provided herein are novel heteroaromatic derivatives, or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a prodrug, a pharmaceutically acceptable salt or a prodrug thereof, and pharmaceutical compositions containing such compounds. Also provided herein are uses of such compounds or pharmaceutical compositions thereof in the manufacture of a medicament for treating respiratory diseases, especially chronic obstructive pulmonary disease (COPD).

METHOD FOR PRODUCING OXAZOLE COMPOUND

An object of the present invention is to provide a novel method for producing an oxazole compound. The invention relates to a method for producing a compound represented by formula (1): wherein R1 is lower alkyl group or halogen substituted lower alkyl group, R2 is lower alkyl group, R5 is lower alkyl group, R11 is lower alkyl group, halogen substituted lower alkyl group or a group represented by formula: -CY2COOR12, wherein Y is a halogen atom, R12 is an alkali metal atom or lower alkyl group, Ar1 is phenyl group substituted with lower alkyl group, etc., or pyridyl group substituted with lower alkyl group, etc., X2, X3 and X9 are the same or different and are halogen atoms, X4 is a leaving group, and M is an alkali metal atom.

Rational design of inhibitors of the bacterial cell wall synthetic enzyme GlmU using virtual screening and lead-hopping

An aminoquinazoline series targeting the essential bacterial enzyme GlmU (uridyltransferase) were previously reported (Biochem. J. 2012, 446, 405). In this study, we further explored SAR through a combination of traditional medicinal chemistry and structure-based drug design, resulting in a novel scaffold (benzamide) with selectivity against protein kinases. Virtual screening identified fragments that could be fused into the core scaffold, exploiting additional binding interactions and thus improving potency. These efforts resulted in a hybrid compound with target potency increased by a 1000-fold, while maintaining selectivity against selected protein kinases and an improved level of solubility and protein binding. Despite these significant improvements no significant antibacterial activity was yet observed within this class.

Discovery and structural modification of 1-phenyl-3-(1-phenylethyl)urea derivatives as inhibitors of complement

A series of 1-phenyl-3-(1-phenylethyl)urea derivatives were identified as novel and potent complement inhibitors through structural modification of the original compound from high-throughput screening. Various analogues (7 and 13-15) were synthesized and identified as complement inhibitors, with the introduction of a five- or six-carbon chain (7c, 7d, 7k, 7l, and 7o) greatly improving their activity. Optimized compound 7l has an excellent inhibition activity with IC50 values as low as 13 nM. We demonstrated that the compound 7l inhibited C9 deposition through the classical, the lectin, and the alternative pathways but had no influence on C3 and C4 depositions.

Divergent synthesis of lamellarin α 13-sulfate, 20-sulfate, and 13,20-disulfate

A divergent synthesis of three sulfate derivatives of lamellarin α, namely, lamellarin α 13-sulfate (2), 20-sulfate (1), and 13,20-disulfate (4) has been achieved via a common intermediate (6) in which 13-OH and 20-OH of the lamellarin core are differentially protected by MOM and benzyl groups, respectively. Compound (6) in turn was prepared using sequential Suzuki-Miyaura coupling of 3,4-dihydroxypyrrole bistriflate (7) as a key reaction.